Corsera Health Raises $80M Series A as Preventative Cardiovascular siRNA Therapy Enters Clinical Testing
Key Insights
Corsera Health (search) secured $80 million in Series A funding co-led by Forbion (search) and Population Health Partners (search) to advance its preventative cardiovascular disease (search) programs.
The company's lead siRNA therapy COR-1004 (search), targeting PCSK9 to lower LDL cholesterol, has entered Phase I clinical trials with dosing underway and proof-of-concept data expected this year.
Founded by biotech veterans John Maraganore and Clive Meanwell, Corsera aims to develop once-yearly treatments combined with AI-enabled risk prediction tools to prevent atherosclerotic cardiovascular disease (search).
Cardiovascular disease (search) biotech Corsera Health (search) has raised $80 million in Series A funding while advancing its first preventative siRNA therapy into clinical testing, marking a significant milestone for the company that emerged during a challenging fundraising environment in 2025.
The funding round was co-led by Forbion (search) and Population Health Partners (search), with participation from co-founder and CEO John Maraganore, the former CEO of Alnylam Pharmaceuticals. The company was also named as one of BioSpace's NextGen Class of 2026 companies to watch, recognizing its potential in the competitive cardiovascular therapeutics space.
Novel Approach to Cardiovascular Prevention
Corsera aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular disease (search) (ASCVD) through a unique combination of AI-enabled predictive tools and once-yearly siRNA treatments. The company is developing an AI-enabled tool to predict lifetime ASCVD risk, which will be paired with therapies designed for annual administration to prevent cardiovascular disease (search).
The biotech's approach focuses on two key therapeutic programs using siRNA technology to silence specific disease-related targets. The lead program, COR-1004 (search), targets PCSK9 protein to lower LDL cholesterol levels, while the second program, COR-2003 (search), aims to reduce blood pressure by targeting angiotensinogen (search) (AGT (search)).
Clinical Milestone Achieved
Corsera announced that COR-1004 (search) has entered Phase I clinical trials, with dosing already underway. This initial study will examine the safety and tolerability of the injectable siRNA therapy, with secondary endpoints measuring clinical activity. Specifically, researchers will monitor the therapy's ability to reduce plasma PCSK9 levels and serum LDL-C concentrations.
The company expects to report initial proof-of-concept data from this Phase I trial later this year, which will provide crucial insights into the therapy's potential effectiveness. Corsera also plans to initiate Phase I testing for COR-2003 (search), its blood pressure-targeting program.
Veteran Leadership in Challenging Market
The company was founded by two prominent biotech veterans: John Maraganore, former CEO of Alnylam, and Clive Meanwell, who cofounded and led Metsera as CEO. Their combined expertise in RNA therapeutics and cardiovascular medicine positions Corsera to navigate the competitive landscape.
Corsera's emergence in September 2025 came during a particularly challenging period for biotech funding. According to industry analysis, capital flow to early-stage biotechs tightened in 2025 as investors shifted toward later-stage, data-driven investments following underperformance of pandemic-era biotech investments.
Despite these market headwinds, Corsera managed to secure significant funding, demonstrating investor confidence in its preventative cardiovascular approach and the track record of its founding team. The company's inclusion in BioSpace's NextGen Class of 2026 further validates its potential impact in addressing cardiovascular disease (search), which remains a leading cause of mortality globally.